Фармакоэкономическая оценка использования препарата Траватан (травопрост) в лечении первичной открытоугольной глаукомы

Р. И. Ягудина, Д. О. Асестров, V.G. Serpik · Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология · 2011

Pharmacoeconomic study of primary open-angle glaucoma treatment with prostaglandin analogues was conducted. Its results demonstrated that Travatan (travoprost) is dominated, has benefit in efficacy over Ksalatan (latanoprost), provides cost-saving and lower cost-effectiveness ratio in comparison to Ksalatan. Replacement of Ksalatan on Travatan provides 1 091 RUB. of costsaving per patient per year from the budget impact analysis perspective. Cost-effectiveness ratio, the cost of successful control for disease for one year, for Travatan was 16 512 and for Ksalatan 17 588 (discounted at 3%).

Cited by 0 works.

Authors